Synopsis Background The UK Medicines and Regulatory Healthcare Agency (MHRA) have
recently licensed the anti-viral drug, molnupiravir, for use in patients with mild-moderate …

The SARS-CoV-2 pandemic has highlighted the need for broad-spectrum antiviral drugs to
respond promptly to viral emergence. We conducted a preclinical study of molnupiravir …

Background Molnupiravir was licensed for treating high-risk patients with COVID-19 based
on data from unvaccinated adults. AGILE CST-2 (NCT04746183) Phase II reports safety and …

Background The antiviral drug molnupiravir was licensed for treating at-risk patients with
COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety …

Real-life experience of molnupiravir treatment is lacking, especially in people hospitalized
for underlying diseases not related to COVID-19. We conducted a retrospective analysis …

Since the start of the severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)
pandemic, several treatments have been proposed to cure coronavirus disease 2019 …

Background Molnupiravir is an oral prodrug of β-d-N4-hydroxycytidine, active against SARS-
CoV-2 in vitro and in animal models. We report data from the phase 2 component of MOVe …

Objectives AGILE is a Phase Ib/IIa platform for rapidly evaluating COVID-19 treatments. In
this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in …

Background The real-world effectiveness of molnupiravir (MOL) during the dominance of
Omicron SARS-CoV-2 lineage is urgently needed since the available data relate to the …

Background Safe and effective oral treatments are needed to improve clinical outcomes for
nonhospitalized patients with Covid-19. Molnupiravir is an orally administered, small …